and subsequently had a positive 89 Zr-DFO-girentuximab scan: Dr. Shuch concluded his presentation by discussing results from ZIRCON, a phase 3 study of 89 Zr-DFO-girentuximab for PET/CT imaging of ...

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

or advanced systemic therapy for prostate cancer. Data analysis included 182 patients who had a median pre-scan PSA level of 2.6 ng/mL Overall, 84% of the patients had positive PSMA-PET/CT results ...

Professor Peter Mulders presented results from the phase 3 ZIRCON study, which evaluated 89 Zr-DFO-girentuximab for PET/CT imaging of clear cell renal ... recent advancements in PSMA imaging in ...

FDG-PET imaging is not routinely employed in this type of cancer and its role in endometrial ... and/or causes hydronephrosis or nonfunctioning kidney T3 IIIA Tumor involves lower third of vagina ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center, published in JAMA Network Open, shows that nearly half of the ...

Cancer patients are skipping scans because they’re too expensive. Picture: Supplied “It’s that double whammy of a cancer diagnosis impacting on people’s ability to work at the same time as ...

Although most people have two kidneys, only one kidney can function just as well as two. You may need to take some precautions to avoid injury to your kidney, though, and see a doctor for regular ...

“The diagnosis was devastating—late-stage kidney failure, with only months to a year left to live,” says Ezyk. “The bill for the bloodwork and other tests came to around $1,000. My pet ...